Aviva’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aviva’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-363,032	Closed	-$690K	–	888
2024 Q2	$690K	Buy	363,032 +217,614	+150%	+$422K	﹤0.01%	679
2024 Q1	$413K	Buy	+145,418	New	+$1.9M	﹤0.01%	894

Other funds holding AMLX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Aviva's AMLX Position: Q3 2024 in Review

Aviva sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 363,032 shares — an estimated $690K sold.

Aviva first reported a position in AMLX in Q1 2024 and held it in 2 quarters. The position peaked at $690K in Q2 2024. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

Aviva reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Aviva sold 363,032 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $690K.
Aviva first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 2 quarters.
Aviva's Amylyx Pharmaceuticals position peaked at $690K in Q2 2024.
110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Aviva's 13F filing for Q3 2024, filed 14 Nov 2024.